Natixis Advisors
ANIP icon

Natixis Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Natixis Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,807
Closed -$1.45M – 1594
2025
Q3 		$1.45M Sell
15,807
-3,095
-16% -$252K ﹤0.01% 1206
2025
Q2 		$1.23M Buy
18,902
+166
+0.9% +$10.8K ﹤0.01% 1236
2025
Q1 		$1.25M Buy
18,736
+135
+0.7% +$8.06K ﹤0.01% 1217
2024
Q4 		$1.03M Buy
18,601
+417
+2% +$23.9K ﹤0.01% 1297
2024
Q3 		$1.08M Buy
18,184
+6,545
+56% +$399K ﹤0.01% 1270
2024
Q2 		$741K Buy
+11,639
New +$756K ﹤0.01% 1341

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Natixis Advisors's ANIP Position: Q4 2025 in Review

Natixis Advisors sold out of ANI Pharmaceuticals (ANIP) in Q4 2025, closing a stake of 15,807 shares — an estimated $1.45M sold.

Natixis Advisors first reported a position in ANIP in Q2 2024 and held it in 6 quarters. The position peaked at $1.45M in Q3 2025. 284 funds tracked by Wall St. Rank hold ANIP as of Q4 2025.

  • Natixis Advisors reported no remaining ANI Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Natixis Advisors sold 15,807 ANI Pharmaceuticals shares in Q4 2025, an estimated $1.45M.
  • Natixis Advisors first reported a position in ANI Pharmaceuticals in Q2 2024 and held it in 6 quarters.
  • Natixis Advisors's ANI Pharmaceuticals position peaked at $1.45M in Q3 2025.
  • 284 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2025.

Based on Natixis Advisors's 13F filing for Q4 2025, filed 10 Feb 2026.